Hepatitis C virus : risk factors and disease progression
暂无分享,去创建一个
B. Grady | T. Heijman | B.P.X. Grady | M. S. Loeff | A. Speksnijder | Ronald B. Geskus | Bart PX Grady | Nienke van der Knaap | Maria Prins
[1] T. Hallett,et al. HIV and risk environment for injecting drug users: the past, present, and future , 2010, The Lancet.
[2] Matthew Hickman,et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage , 2010, The Lancet.
[3] J. V. D. van der Meer,et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. , 2007, The Journal of infectious diseases.
[4] N. Hilzenrat,et al. Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region Sequences , 2007, Journal of Clinical Microbiology.
[5] C. Bucello,et al. Mortality among people who inject drugs: a systematic review and meta-analysis. , 2013, Bulletin of the World Health Organization.
[6] D. Vlahov,et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.
[7] A. K. van der Bij,et al. Effectiveness of a Risk-Based Visitor-Prioritizing System at a Sexually Transmitted Infection Outpatient Clinic , 2006, Sexually transmitted diseases.
[8] Michael P. Busch,et al. Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates , 2007, Journal of Clinical Microbiology.
[9] R. Geskus,et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 , 2011, AIDS.
[10] D. Thabut,et al. Natural history and predictors of disease severity in chronic hepatitis C. , 2006, Journal of hepatology.
[11] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[12] M. Kretzschmar,et al. Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study , 2014, AIDS (London).
[13] M. Alary,et al. Temporal changes in risk factors associated with HIV seroconversion among injection drug users in eastern central Canada , 2011, AIDS.
[14] M. Ostrowski,et al. Comparison of Immune Restoration in Early versus Late Alpha Interferon Therapy against Hepatitis C Virus , 2010, Journal of Virology.
[15] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[16] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[17] J. Raffa,et al. Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.
[18] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[19] M. Prins,et al. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study , 2006, AIDS.
[20] B. Edlin,et al. Sex‐ and Drug‐Related Risk Among Populations of Younger and Older Injection Drug Users in Adjacent Neighborhoods in San Francisco , 2000, Journal of acquired immune deficiency syndromes.
[21] M. Langendam,et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands , 2005, Journal of medical virology.
[22] A. Wensing,et al. Pegylated Interferon-α Monotherapy Leads to Low Response Rates in HIV-Infected Patients with Acute Hepatitis C , 2011, Antiviral therapy.
[23] David L. Thomas,et al. Hepatitis C virus vaccines among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] P. Schürmann,et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.
[25] S. Walters,et al. High-risk drug use and sexual behaviors among out-of-treatment drug users: an aging and life course perspective. , 2010, Addictive behaviors.
[26] A. Hatzakis,et al. Economic Recession and Emergence of an HIV-1 Outbreak among Drug Injectors in Athens Metropolitan Area: A Longitudinal Study , 2013, PloS one.
[27] D. Vlahov,et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] R. Geskus,et al. Distinct Neisseria gonorrhoeae transmission networks among men who have sex with men in Amsterdam, The Netherlands. , 2012, The Journal of infectious diseases.
[29] G. Lauer,et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C , 2005, Hepatology.
[30] O. Pybus,et al. The hepatitis C virus epidemic among injecting drug users. , 2005, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[31] R A Coutinho,et al. Clinical Sexually Transmitted Diseases Among Human Immunodeficiency Virus‐Infected and Noninfected Drug‐Using Prostitutes: Associated Factors and Interpretation of Trends, 1986 to 1994 , 1997, Sexually transmitted diseases.
[32] J. Ticehurst,et al. Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis , 2007, Journal of Clinical Microbiology.
[33] M. Pirisi,et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. , 2011, Journal of hepatology.
[34] S. Kamal. Acute Hepatitis C: A Systematic Review , 2008, The American Journal of Gastroenterology.
[35] M. Carrington,et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. , 2014, Gastroenterology.
[36] E. Penner,et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load , 2003, Hepatology.
[37] Pete J. Frost,et al. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C , 2010, Journal of gastroenterology and hepatology.
[38] R. Booth,et al. HIV Risk Behaviors Among Older American Drug Users , 2003, Journal of acquired immune deficiency syndromes.
[39] R. Effros. Genetic alterations in the ageing immune system: impact on infection and cancer , 2003, Mechanisms of Ageing and Development.
[40] H. Götz,et al. HIV AND SExUAL RISk bEHAVIOUR AmONG COmmERCIAL SEx wORkERS IN THE NETHERLANDS , 2010 .
[41] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[42] M. Alavi,et al. Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[43] A. Alberti. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[44] R. D. de Knegt,et al. Randomised clinical trial: anti‐viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV , 2011, Alimentary pharmacology & therapeutics.
[45] Sally Caglioti,et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.
[46] Julia E. Vogt,et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. , 2011, Gastroenterology.
[47] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[48] L. Maher. Hepatitis B vaccination and injecting drug use: narrowing the efficacy-effectiveness gap. , 2008, The International journal on drug policy.
[49] M. Lafrenz,et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. , 2005, Journal of hepatology.
[50] H. Innes,et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.
[51] H. Wedemeyer,et al. Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.
[52] R. Garfein,et al. Distributive syringe sharing among young adult injection drug users in five U.S. cities. , 2007, Drug and alcohol dependence.
[53] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[54] G. Schippers,et al. Motives for and Against Injecting Drug Use Among Young Adults in Amsterdam: Qualitative Findings and Considerations for Disease Prevention , 2006, Substance use & misuse.
[55] S. Glynn,et al. Dynamics of viremia in early hepatitis C virus infection , 2005, Transfusion.
[56] R. Geskus,et al. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study , 2004, AIDS.
[57] J. Kaldor,et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia , 2009, Sexually Transmitted Infections.
[58] M. Young,et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. , 2010, The Journal of infectious diseases.
[59] J. Blackard,et al. Hepatitis C virus coinfection and superinfection. , 2007, The Journal of infectious diseases.
[60] Todd M. Allen,et al. CD8 Epitope Escape and Reversion in Acute HCV Infection , 2004, The Journal of experimental medicine.
[61] J. Lazarus,et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.
[62] R. Klein. Trends Related to Aging and Co-Occurring Disorders in HIV-Infected Drug Users , 2011, Substance use & misuse.
[63] D. Vlahov,et al. Protection against persistence of hepatitis C , 2002, The Lancet.
[64] S. Currie,et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. , 2008, Drug and alcohol dependence.
[65] M. Houghton,et al. Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C , 1998 .
[66] S. Hamid,et al. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan , 2010, Journal of viral hepatitis.
[67] M. Kretzschmar,et al. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? , 2013, Addiction.
[68] R. Heimer,et al. The Potential for Bridging of HIV Transmission in the Russian Federation: Sex Risk Behaviors and HIV Prevalence among Drug Users (DUs) and their Non-DU Sex Partners , 2009, Journal of Urban Health.
[69] J. Kaldor,et al. Dynamics of HCV RNA levels during acute hepatitis C virus infection , 2014, Journal of medical virology.
[70] J. Kaldor,et al. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. , 2013, American journal of public health.
[71] Inda,et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.
[72] G. Lauer,et al. Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. , 2013, International journal of epidemiology.
[73] D. D. Des Jarlais,et al. Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .
[74] M. Alter,et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. , 2005, The Journal of infectious diseases.
[75] Leber,et al. Extrahepatische Manifestationen der chronischen Hepatitis-C-Virus-Infektion , 2009, Zeitschrift fur Gastroenterologie.
[76] R. Geskus,et al. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study , 2015, Journal of viral hepatitis.
[77] T. To,et al. Spontaneous clearance of childhood hepatitis C virus infection , 2007, Journal of viral hepatitis.
[78] M. Ostrowski,et al. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. , 2008, Gastroenterology.
[79] R. Geskus,et al. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. , 2006, Addiction.
[80] R. Molenkamp,et al. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[81] M. Heim,et al. Innate and adaptive immune responses in HCV infections. , 2014, Journal of hepatology.
[82] G. Schippers,et al. Transitions in Drug Use in a New Generation of Problem Drug Users in Amsterdam: a 6-Year Follow-Up Study , 2009, European Addiction Research.
[83] F. Negro. Hepatitis C in 2013: HCV causes systemic disorders that can be cured , 2014, Nature Reviews Gastroenterology &Hepatology.
[84] N. Janjua,et al. Poor knowledge – predictor of nonadherence to universal precautions for blood borne pathogens at first level care facilities in Pakistan , 2007, BMC infectious diseases.
[85] J. Parry,et al. Risk of sexually transmitted infections and violence among indoor-working female sex workers in London: the effect of migration from Eastern Europe , 2011, Sexually Transmitted Infections.
[86] J. V. D. van der Meer,et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.
[87] C. Sabin,et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. , 2013, Gastroenterology.
[88] H. Nagano,et al. Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon‐λ in response to hepatitis C virus , 2013, Hepatology.
[89] O. Dalgard. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] S. Currie,et al. Corrigendum to “A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus” [Drug Alcohol Depend. 93(1–2) (2008) 148–154] , 2008 .
[91] E. Delwart,et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[92] M. Abdel-hamid,et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt , 2010, Gut.
[93] M. Hellard,et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[94] Anne M Johnson,et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.
[95] J. Kaldor,et al. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. , 2007, AIDS.
[96] R. Rothenberg,et al. Special Issue: Sexual Acquisition and Transmission of HIV Cooperative Agreement Program (SATHCAP), July 2009 , 2009, Journal of Urban Health.
[97] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[98] G. Dore,et al. Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.
[99] M. Busch,et al. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[100] M. Kretzschmar,et al. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? , 2015, Addiction.
[101] D. Vlahov,et al. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. , 2005, AIDS.
[102] F. Marincola,et al. HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations , 2012, Hepatology.
[103] P Parham,et al. Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.
[104] M. Nelson,et al. Acute hepatitis C infection in HIV‐negative men who have sex with men , 2015, Journal of viral hepatitis.
[105] S. Ray,et al. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution , 2012, Hepatology.
[106] C. Hagedorn,et al. IL-1β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease , 2013, PLoS pathogens.
[107] J. Hanley,et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. , 2003, American journal of epidemiology.
[108] Evan Wood,et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study , 2009, BMJ : British Medical Journal.
[109] J. Bukh,et al. Hepatitis C Virus Subtyping by a Core-Envelope 1-Based Reverse Transcriptase PCR Assay with Sequencing and Its Use in Determining Subtype Distribution among Danish Patients , 2003, Journal of Clinical Microbiology.
[110] G. Dore,et al. Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.
[111] Daniel M. Hartung,et al. Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review , 2013, Annals of Internal Medicine.
[112] M. Hellard,et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.
[113] Z. Kutalik,et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C , 2014, Gut.
[114] J. Guydish,et al. Injection Risk Behavior among Women Syringe Exchangers in San Francisco , 2005, Substance use & misuse.
[115] Louisa Degenhardt,et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.
[116] W. Paxton,et al. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. , 2011, Sexually transmitted diseases.
[117] R. Hogg,et al. The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia. , 2005, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[118] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[119] B. Edlin. Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.
[120] M. Kretzschmar,et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. , 2012, Addiction.
[121] M. Massari,et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[122] Nancy Glass,et al. Global burden of hepatitis C: considerations for healthcare providers in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[123] B. Conway,et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users , 2009, Journal of gastroenterology and hepatology.
[124] H. J. Vriend,et al. Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? , 2011, Journal of hepatology.
[125] R. Tibshirani,et al. Generalized Additive Models , 1986 .
[126] M. Alary,et al. Injection drug use, commercial sex work, and the HIV/STI epidemic in the Russian Federation. , 2003, Sexually transmitted diseases.
[127] Hsin-Yun Sun,et al. Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors , 2011, Journal of Clinical Microbiology.
[128] L. Thorpe,et al. Prevalence and Incidence of HIV Among Out‐of‐Treatment Injecting Drug Users, Chicago 1994‐1996 , 2000, Journal of acquired immune deficiency syndromes.
[129] B. Grady,et al. Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort , 2011, PloS one.
[130] Todd M. Allen,et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence , 2012, The Journal of experimental medicine.
[131] R. Cawthon,et al. Short Telomere Length, Myocardial Infarction, Ischemic Heart Disease, and Early Death , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[132] J. Nattermann,et al. Different distributions of hepatitis C virus genotypes among HIV‐infected patients with acute and chronic hepatitis C according to interleukin‐28B genotype , 2011, HIV medicine.
[133] X. Lao,et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. , 2010, Gastroenterology.
[134] M. J. Minkin. Sexually transmitted infections and the aging female: placing risks in perspective. , 2010, Maturitas.
[135] H. Hackstein,et al. TLR7 ligands induce higher IFN-alpha production in females. , 2006, Journal of immunology.
[136] L. Avanesyan,et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. , 2009, The Journal of infectious diseases.
[137] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[138] B. Conway,et al. Hepatitis C virus reinfection in injection drug users , 2006, Hepatology.
[139] D. D. Des Jarlais,et al. HIV Among Drug Users at Beth Israel Medical Center, New York City, the First 25 Years , 2011, Substance use & misuse.
[140] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[141] T. Liang,et al. Hepatitis C: The End of the Beginning and Possibly the Beginning of the End , 2012, Annals of Internal Medicine.
[142] D. Huo,et al. Needle Exchange and Sexual Risk Behaviors Among a Cohort of Injection Drug Users in Chicago, Illinois , 2009, Sexually transmitted diseases.
[143] R. Weber,et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[144] H. Rosen. Emerging concepts in immunity to hepatitis C virus infection. , 2013, The Journal of clinical investigation.
[145] R. Geskus,et al. Stabilizing Incidence of Hepatitis C Virus Infection Among Men Who Have Sex With Men in Amsterdam , 2014, Journal of acquired immune deficiency syndromes.
[146] P. Klenerman,et al. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. , 2006, Blood.
[147] Todd M. Allen,et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.
[148] J. Goedert,et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. , 2005, Blood.
[149] M. Chang. Mother‐to‐infant transmission of hepatitis C virus , 1995 .
[150] S. Gange,et al. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. , 2011, American journal of epidemiology.
[151] E. Ruiz-Mateos,et al. HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. , 2011, Current HIV research.
[152] M. Memon,et al. Hepatitis C: an epidemiological review , 2002, Journal of viral hepatitis.
[153] G. Alexander,et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? , 2007, Journal of viral hepatitis.
[154] W. Dowdle. The principles of disease elimination and eradication. , 1998, Bulletin of the World Health Organization.
[155] J. Singer,et al. Association between short leukocyte telomere length and HIV infection in a cohort study: No evidence of a relationship with antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[156] L. Dal Maso,et al. Manifestations of chronic hepatitis C virus infection beyond the liver. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[157] G. Dore,et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting , 2010, Hepatology.
[158] H. Wand,et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.
[159] M. Kretzschmar,et al. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. , 2010, Addiction.
[160] P. Bacchetti,et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis , 2001, The Lancet.
[161] H. Siegal,et al. Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility. , 2000, American journal of public health.
[162] R. Garfein,et al. Prevalence and Correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis infections, and Bacterial Vaginosis Among a Cohort of Young Injection Drug Users in Baltimore, Maryland , 2005, Sexually transmitted diseases.
[163] T. Rhodes,et al. Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.
[164] G. Lauer,et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. , 2012, The Lancet. Infectious diseases.
[165] M. Newell,et al. Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe , 2007, European Journal of Epidemiology.
[166] H. J. Vriend,et al. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections , 2012, Epidemiology and Infection.
[167] J. Kaldor,et al. High hepatitis C incidence in new injecting drug users: a policy failure? , 2007, Australian and New Zealand journal of public health.
[168] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[169] Sanaa M Kamal,et al. Hepatitis C genotype 4: What we know and what we don't yet know , 2008, Hepatology.
[170] J. Goudsmit,et al. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. , 1988, AIDS.
[171] J. Ghrayeb,et al. Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.
[172] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[173] R. Molenkamp,et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. , 2009, Journal of hepatology.
[174] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[175] J. Kaldor,et al. Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection , 2010, Hepatology.
[176] S. Lewin,et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. , 2013, The Journal of infectious diseases.
[177] N. Janjua,et al. Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad. , 2004, JPMA. The Journal of the Pakistan Medical Association.
[178] L. Seeff. The history of the “natural history” of hepatitis C (1968–2009) , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[179] Richard D Moore,et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.
[180] P. Vickerman,et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.
[181] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[182] J. Parry,et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size , 2009, Epidemiology and Infection.
[183] R. Geskus,et al. Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era , 2012, AIDS.
[184] B. Grady,et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam , 2012, European journal of gastroenterology & hepatology.
[185] R. Bartenschlager,et al. Analysis of CD8+ T cell-mediated inhibition of hepatitis C virus replication using a novel immunological model , 2009 .
[186] P. Simmonds,et al. Molecular Epidemiology of Hepatitis C Virus , 2002 .
[187] K. Shianna,et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. , 2010, Gastroenterology.
[188] S. Kleinman,et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.
[189] D. Vlahov,et al. Changes in blood-borne infection risk among injection drug users. , 2011, The Journal of infectious diseases.
[190] J. Villeneuve,et al. Early Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8+ Memory T Cells , 2008, Journal of Virology.
[191] J. Goedert,et al. Correlates of high hepatitis C virus RNA load in a cohort of HIV‐negative and HIV‐positive individuals with haemophilia , 2011, Journal of viral hepatitis.
[192] M. Alavi,et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. , 2011, Journal of hepatology.
[193] M. Nei,et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.
[194] N. Hessol,et al. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras , 2005, AIDS.
[195] A. Boonstra,et al. Role of T cell immunity in hepatitis C virus infections. , 2013, Current opinion in virology.
[196] H. Günthard,et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[197] K. Kielland,et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.
[198] S. Zeuzem,et al. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. , 2014, Journal of hepatology.
[199] S. Ray,et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. , 2010, Gastroenterology.
[200] S. Mousa,et al. Recent advances and future directions in the management of hepatitis C infections. , 2015, Pharmacology & therapeutics.
[201] S. Strathdee,et al. Epidemiology of HIV Among Injecting and Non-injecting Drug Users: Current Trends and Implications for Interventions , 2010, Current HIV/AIDS reports.
[202] B. Berkhout,et al. Transmission of Risk-Group Specific HIV-1 Strains Among Dutch Drug Users for More Than 20 Years and Their Replacement by Nonspecific Strains After Switching to Low-Harm Drug Practices , 2013, Journal of acquired immune deficiency syndromes.
[203] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[204] B. Swift,et al. Death certification: an audit of practice entering the 21st century. , 2002, Journal of clinical pathology.
[205] C. Boucher,et al. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. , 2014, The Netherlands journal of medicine.
[206] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[207] O. Pybus,et al. vidence of a Large , International Network of HCV Transmission in HIV-ositive Men Who Have Sex With Men , 2022 .
[208] Margaret Hellard,et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users , 2008, Hepatology.
[209] J. Grebely,et al. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. , 2015, The International journal on drug policy.
[210] B. Gazzard,et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM , 2013, AIDS.
[211] C. Rice,et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. , 2006, Gastroenterology.
[212] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[213] M. Houghton,et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection , 2001, Hepatology.
[214] Judy Gold,et al. Hepatitis C treatment for injection drug users: a review of the available evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[215] T. Asselah,et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy , 2003, Gut.
[216] B. Edlin,et al. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[217] B. Berkhout,et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users , 2007, European Journal of Epidemiology.
[218] B. Lau,et al. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[219] J. Kaldor,et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[220] M. Danta,et al. Sexually transmitted hepatitis C infection: the new epidemic in MSM? , 2012, Current opinion in infectious diseases.
[221] S. Sauleda,et al. The changing epidemiology of hepatitis C virus infection in Europe. , 2008, Journal of hepatology.
[222] R. Bartenschlager,et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. , 2009, Gastroenterology.
[223] S. Holmberg,et al. Is sexual contact a major mode of hepatitis C virus transmission? , 2010, Hepatology.
[224] L. Magder,et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.
[225] N. Savona. Older people are at risk of sexually transmitted infections , 2010, Sexually Transmitted Infections.
[226] M. Gao,et al. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase. , 2006, Analytical biochemistry.
[227] J. Pawlotsky. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. , 2011, Gastroenterology.
[228] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[229] J. Kaldor,et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users , 2007, Journal of viral hepatitis.
[230] Heiyoung Park,et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. , 2012, The Journal of infectious diseases.
[231] T. Asselah,et al. New direct‐acting antivirals' combination for the treatment of chronic hepatitis C , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[232] Martin McKee,et al. Health systems' responses to 25 years of HIV in Europe: inequities persist and challenges remain. , 2008, Health policy.
[233] J. Kaldor,et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection , 2012, Hepatology.
[234] C. Rice,et al. Kinetics of CD4+ and CD8+ Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees , 2003, Journal of Virology.
[235] B. Rehermann,et al. Immune responses to HCV and other hepatitis viruses. , 2014, Immunity.
[236] J. Parry,et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.
[237] T. Liang,et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis , 2013, Hepatology.
[238] K. Bjøro,et al. Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.
[239] G. Lauer,et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection , 2014, Hepatology.
[240] B. Conway,et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. , 2008, Drug and alcohol dependence.
[241] R. Geskus,et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010 , 2014, AIDS.
[242] O. Weiland,et al. Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.
[243] M. Danta,et al. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. , 2010, AIDS.
[244] D. Vlahov,et al. Progress in HIV Reduction and Prevention Among Injection and Noninjection Drug Users , 2010, Journal of acquired immune deficiency syndromes.
[245] A. Craxì,et al. Cardiovascular diseases and HCV infection: a simple association or more? , 2013, Gut.
[246] E. Fish,et al. SeXX matters in immunity. , 2014, Trends in immunology.
[247] Masaya Sugiyama,et al. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[248] S. Ruță,et al. Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. , 2013, Public health.
[249] R. Booth,et al. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. , 2000, Drug and alcohol dependence.
[250] Ayman A. Abd El-Wahab,et al. Prospective cohort study of mother‐to‐infant infection and clearance of hepatitis C in rural Egyptian villages , 2009, Journal of medical virology.
[251] Z. Kutalik,et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. , 2012, Gastroenterology.
[252] R. Coutinho,et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.
[253] A. Branch,et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. , 2008, The Journal of infectious diseases.